MGXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Metagenomi Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$0.81+0.03 (+3.55%)
Close on Oct 19, 2026
- Market cap
- $30.57M
- P/E (TTM)
- –
- Dividend yield
- –
Fundamental chart
Pick a measure to chart its full history
$25.21MFY2025, -24.9% a year since FY2023